Ohio State Navbar

Directory

Joseph Flynn, DO, MPH


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-9321

Email: flynn.154@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Associate Professor-Clinical, COPH -Division of Epidemiology

Physician, FGP-Hematology

 

Clinical Interest

Hematology, Public Health

Research Funding

Lance Armstrong Grant

Academic Advising

2010 - present , The Ohio State University.
2011 - present , The Ohio State University.
2008 - 2009 , The Ohio State University.
2009 - 2010 , The Ohio State University.
2010 , The Ohio State University.
2010 , The Ohio State University.
2009 - 2011 , The Ohio State University.
2010 - 2011 , The Ohio State University.
2011 , The Ohio State University.
 

Certifications

1999 - present Internal Medicine: Philadelphia College of Osteopathy
2003 - present Medical Oncology: Uniformed Services University of the Health Sciences
2007 - present Doctor of Osteopathic Medicine: Ohio State Medical Association
1998 - 2007 Doctor of Osteopathic Medicine: University of The District of Columbia
 

Chapters in Books

Byrd JC, Flynn J. "Chronic lymphocytic leukemia." In Abeloff’s Clinical Oncology. 5 ed. Edited by Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. 158-78. Philadelphia, PA, US|USA: W.B. Saunders Co, October 2013.

 

Clinical Services

08/01/2007 Outpatient Hematology Clinic (2 James, 2 James chemotherapy and CTU, Internal Medicine/Division of Hematology & Oncology)
01/01/2010 OSU East Clinic (Internal Medicine/Division of Hematology)
01/01/2010 Lymphadenopathy Clinic (James Cancer Hospital, Division of Hematology)
08/01/2007 Heme 1 Service (James Cancer Hospital, Internal Medicine/Division of Hematology & Oncology)
10/01/2007 Heme II Service (James Cancer Hospital, Internal Medicine/Division of Hematology and Oncology)
01/01/2008 Hem II Inpatient Service (James Cancer Hospital, Hematology and Oncology)
01/01/2008 Hem I Inpatient Service (James Cancer Hospital, Hematology and Oncology)
03/01/2008 Hem I Inpatient Service (James Cancer Hospital, Hematology and Oncology)
05/01/2008 Hem II Inpatient Service (James Cancer Hospital)
08/01/2008 Hem II Inpatient Service (James Cancer Hospital, Hematology and Oncology)
10/01/2008 Hem II Inpatient Service (James Cancer Hospital, Hematology and Oncology)
12/01/2008 HNP service (James Cancer Hospital, Internal Medicine/Division of Hematology & Oncology)
12/01/2008 Hem I Inpatient Service (James Cancer Hospital, Hematology and Oncology)
03/01/2009 Hem I Inpatient Service (James Cancer Hospital, Division of Hematology and Oncology)
05/01/2009 Hem II Inpatient Service (James Cancer Hospital, Division of Hematology and Oncology)
07/01/2009 Hem II Service (James Cancer Hospital)
07/01/2009 - 08/01/2009 Hem I Inpatient Service (James Cancer Hospital, Division of Hematology and Oncology)
10/01/2009 Hem I Inpatient Service (James Cancer Hospital, Internal Medicine/Division of Hematology & Oncology)
02/01/2010 Hem II Inpatient Service (James Cancer Hospital, Division of Hematology/Oncology)
04/01/2010 Hem I Inpatient Service (James Cancer Hospital, Department of Hematology/Oncology)
05/01/2010 HNP Service (James Cancer Hospital, Division of Hematology/Oncology)
07/01/2010 Hem II Inpatient Service (James Cancer Hospital, Internal Medicine)
07/01/2010 Hem II Inpatient Service (James Cancer Hospital, Division of Hematology/Oncology)
08/01/2010 HNP Service (James Cancer Hospital, Division of Hematology)
08/01/2010 HNP Inpatient Service (James Cancer Hospital, Internal Medicine)
11/01/2010 Hem I Inpatient Service (James Cancer Hospital, Internal Medicine)
01/01/2011 Hem I Inpatient Service (James Cancer Hospital, Internal Medicine)
02/01/2011 Hem I Inpatient Service (James Cancer Hospital, Internal Medicine)
04/01/2011 Hem I Inpatient Service (James Cancer Hospital, Internal Medicine)
05/01/2011 Hem I Inpatient Service (James Cancer Hospital, Internal Medicine)
08/01/2011 Hematology Inpatient Consults (OSU East Hospital)
09/01/2011 Hematology Inpatient Consults (James Cancer Hospital)
11/01/2011 Hem I Inpatient Service (James Cancer Hospital)
12/01/2011 Hematology HNP Service (James Cancer Hospital)
02/01/2012 Hem I Inpatient Service (James Cancer Hospital)
04/01/2012 Hematology HNP Service (James Cancer Hospital)
06/01/2012 Hematology I Inpatient Service (James Cancer Hospital)

Degrees

1985 B.A., Skidmore College

1991 M.B.A., Babson College

1996 D.O., Philadelphia College of Osteopathy

2002 M.Public Hlth., Uniformed Services University of the Health Sciences

 

Editorial Activities

2001 - 2004 Journal of Clinical Immunology
2001 - 2005 Air Force Office of Scientific Research
2009 - present British Journal of Hematology
2009 - present Leukemia & Lymphoma
2011 - present Cancer
2014 - present Blood
 

Honors

1997 Certificate of Appreciation.
1997 Certificate of Appreciation. Hematology-Oncology Ward Staff and Patients.
1997 First Place, Scientific Presentation. American College of Physicians, Regional Associates Meeting.
1997 First Place - Scientific Presentation.
1997 - 2005 Army Achievement Medal (3 Oak Leaf Clusters). 1997, 1999, 2002, 2005.
1998 Co-author of Clinical Practice Guidelines for Nonsteroidal Anti-inflammatory Drug Usage. North Atlantic Regional Medical Command.
1999 James Leonard Award - Outstanding Medical Resident.
1999 Alpha Omega Alpha Medical Honor Society.
1999 Bailey K. Ashford Research Award Semifinalist.
1999 - 2002 Army Commendation Medal (2 Oak Leaf Clusters).
2001 Proposed and Developed the Drug Development Program for Phase I Clinical Trials. Walter Reed Army Medical Center.
2002 Bailey K. Ashford Research Award Finalist.
2002 Venture Capital Initiative for Expanded Oncology Practice. Department of Defense.
2002 Mosby Reasearch Award Finalist.
2002 - 2006 Department of Defense, Venture Capital Initiative for Expanded Oncology Practice. Landstuhl Regional Medical Center.
2003 Global War on Terrorism Service Medal.
2004 Overseas Ribbon.
2004 Superior Unit Citation.
2004 - 2005 Commander's Award for Customer Service.
2005 Meritorious Unit Citation.
2005 Meritorious Service Medal (2 Oak Leaf Clusters) 2005, 2006, 2007.
2005 Tricare Heroes of the Year Award Winner.
2005 Developed Proposal for Deployment of Wireless Electronic Medical Record System. Landstuhl Regional Medical Center.
2006 Non-Article 5 NATO Medal.
2009 Dr. John D. Kenny National Award. Leukemia & Lymphoma Society, White Plains, NY.
2010 Examiner for 2010 Malcolm Baldridge National Quality Award. Department of Commerce.
2015 - present Physician Champion of Nursing Award. The James Magnet Council and Professional Development Council.
 

Journal Articles

George-Weinstein M, Gerhart J, Reed R, Flynn JM, allahan B, Mattiacci M, Miehle C, Foti G, Lash JW, Weintraub W.. "Skeletal Myogenesis: The Preferred Pathway of Chick Embryo Epiblase Cells in vitro.." Developmental Biology. Vol. 173, (January 1996.): 279-291.

Waselenko JK, Flynn JM, Byrd JC. "Stem-cell transplantation in chronic lymphocytic leukemia: The time for designing randomized studies has arrived." Seminars in Oncology. Vol. 26, no. 1. (February 1999.): 48-61.

Flynn JM, Byrd JC. "Campath-1H monoclonal antibody therapy." CURRENT OPINION IN ONCOLOGY. Vol. 12, no. 6. (November 2000.): 574-581.

Shorr AF, McVeigh SK, Flynn JM, Moores LK.. "Intensive Care Unit Outcomes for Patients with Thrombotic Thrombocytopenic Purpura.." Clinical Intensive Care. Vol. 12, no. 2. (January 2001.): 73-79.

Baranko D, Flynn JM, Blanchard J. "Hemachromatosis as a Risk Factor for Fulminant Staphylococcus Aureus Pneumonia." Infectious Diseases in Clinical practice. Vol. 10, (January 2001.): 44-.

Flynn JM,Byrd JC. "Thrice Weekly rituximab therapy in a patient with chronic lymphocytic leukemia." Case Studies Lymphoma. Vol. 13, no. 3. (September 2001.): 1-8.

Ales N, Flynn J, Byrd JC. "Novel Presentation of Acute Myelogenous Leukemia as Symptomatic Galactorrhea." ANNALS OF INTERNAL MEDICINE. Vol. 135, no. 4. (August 2001.): 303-304.

Drabick JJ, Davis BJ, Lichy JH, Flynn J, Byrd JC. "Human herpesvirus 8 genome is not found in whole bone marrow core biopsy specimens of patients with plasma cell dyscrasias." ANNALS OF HEMATOLOGY. Vol. 81, no. 6. (June 2002.): 304-307.

Perkins JG, Flynn JM, Howard RS, Byrd JC. "Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma - Implications for clinical trials in this patient population." Cancer. Vol. 94, no. 7. (April 2002.): 2033-2039.

Flynn J, Byrd JC.. "Campath-1H: A promising new therapy for chronic lymphocytic leukemia." South Car Med. (January 2002.): -.

Flynn JM, Byrd, John C. "Have we forgotten the purpose of phase III studies?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 25, no. 35. (January 2007.): 5553-5.

Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, Brechbiel MW. "Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease." CLINICAL CANCER RESEARCH. Vol. 13, no. 6. (March 2007.): 1926-1935.

Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ, Flynn J, Brechbiel MW. "Multimodality therapy: Potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease." CLINICAL CANCER RESEARCH. Vol. 14, no. 16. (August 2008.): 5108-5115.

Flynn JM, Byrd JC. "In Reply." J Clin Oncol. (May 2008.): 2412-2413.

Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. "Lymphoma in Adolescents and Young Adults." Seminars in Oncology. Vol. 36, no. 5. (October 2009.): 381-418.

Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. "Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease." JOURNAL OF CLINICAL ONCOLOGY. Vol. 27, no. 35. (December 2009.): 6012-6018.

Flynn JM, Andritsos L, Lucas D, Byrd JC. "Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 149, no. 3. (May 2010.): 388-390.

Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC. "Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 150, no. 2. (July 2010.): 189-195.

Herman SEM, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ. "Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals." Blood. Vol. 116, no. 12. (September 2010.): 2078-2088.

Woyach JA, Heerema NA, Zhao J, McFaddin A, Stark A, Lin TS, Andritsos LA, Blum KA, Flynn JM, Jones JA, Byrd JC. "Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 148, no. 5. (March 2010.): 754-759.

Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC. "CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody." Blood. Vol. 115, no. 6. (February 2010.): 1204-1213.

Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765." BLOOD. Vol. 117, no. 23. (June 2011.): 6287-6296.

Muthusamy N, Breidenbach H, Andritsos L, Flynn J, Jones J, Ramanunni A, Mo X, Jarjoura D, Byrd JC, Heerema NA. "Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate." CANCER GENETICS. Vol. 204, no. 2. (February 2011.): 77-83.

Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. "Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol." Leukemia. Vol. 25, no. 9. (September 2011.): 1444-1451.

Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. "Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma." CANCER. Vol. 117, no. 11. (June 2011.): 2442-2451.

Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC. "Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. Vol. 97, no. 3. (March 2012.): 423-427.

Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC. "Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals." Cancer Cell. Vol. 21, no. 5. (May 2012.): 694-708.

Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL, Yeh YY, Andritsos L, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JC.. "ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.." Blood. Vol. 120, no. 6. (August 2012.): 1262-1273.

Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LA.. "Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.." Br J Haematol. Vol. 159, no. 1. (October 2012.): 82-87.

Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Pappo AS, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack BJ, Sundar H, Shead DA.. "Adolescent and Young Adult Oncology.." J Natl Compr Canc Netw. Vol. 10, no. 9. (September 2012.): 1112-1150.

Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, Flynn J, Jones J, Zhang X, Bannerji R, Grever MR, Byrd JC.. "The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.." Leukemia. Vol. 26, no. 12. (December 2012.): 2554-2557.

Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Heerema NA, Byrd JC. "Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features." Leukemia. Vol. 26, no. 6. (June 2012.): 1442-1444.

Salem G, Flynn JM, Cataland SR. "Profound neurological injury in a patient with atypical hemolytic uremic syndrome." Annals Of Hematology. Vol. 92, no. 4. (April 2013.): 557-558.

Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N. "Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies." Mabs. Vol. 5, no. 5. (September 2013.): 723-735.

Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM, Flynn J, Andritsos LA, Devine SM, Blum KA. "Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma." Bone Marrow Transplantation. Vol. 48, no. 9. (September 2013.): 1212-1217.

Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd, JC, Flynn JM. "Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia." Leukemia Research. Vol. 37, no. 10. (October 2013.): 1195-1199.

Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. "Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes." Blood. Vol. 122, no. 15. (October 2013.): 2539-2549.

Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N. "Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing." Blood. Vol. 122, no. 19. (November 2013.): 3308-3316.

Mahoney E, Maddocks K, Flynn J, Jones J, Cole SL, Zhang X, Byrd JC, Johnson AJ. "Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies." Leukemia & Lymphoma. Vol. 54, no. 12. (December 2013.): 2685-2692.

Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. "Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma." American Journal Of Hematology. Vol. 89, no. 1. (January 2014.): 19-24.

Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipp TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. "Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy." Blood. Vol. 123, no. 12. (March 2014.): 1810-1817.

Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, Andritsos LA, McCauley D, Shacham S, Kauffman M, Byrd JC, Lapalombella R. "Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells." Leukemia. Vol. 28, no. 5. (May 2014.): 1158-1163.

Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA. "A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia." Leukemia Research. Vol. 38, no. 9. (September 2014.): 1025-1029.

Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC. "Ocaratuzumab, an Fc- engineered antibody demonstrates enhanced antibody- dependent cell- mediated cytotoxicity in chronic lymphocytic leukemia." Mabs. Vol. 6, no. 3. (May 2014.): 748-754.

Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski S, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. "Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center." Leukemia. Vol. 28, no. 6. (June 2014.): 1365-1368.

Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KA. "Complete Response to Induction Therapy in Patients With Myc-Positive and Double-Hit Non-Hodgkin Lymphoma Is Associated With Prolonged Progression-Free Survival." Cancer. Vol. 120, no. 11. (June 2014.): 1677-1685.

Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N. "The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model." Leukemia. Vol. 28, no. 7. (July 2014.): 1501-1510.

Byrd JC, Jones JJ, Woyach JA, Johnson,AJ, Flynn JM. "Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician." Journal Of Clinical Oncology. Vol. 32, no. 27. (September 2014.): 3039-3047.

Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, BlumKA. "A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma." Blood. Vol. 125, no. 2. (January 2015.): 242-248.

Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. "Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia." Leukemia. Vol. 29, no. 2. (February 2015.): 346-355.

Hofmeister CC, Williams N Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM Blum K, Porcu P, Flynn J, Penza Sam, Benson DM, Andritsos LA, Devine SM. "A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma." Leukemia & Lymphoma. Vol. 56, no. 4. (April 2015.): 1043-1049.

Cohen JB, Ruppert AS, Heerema NA, Andritsos LA, Jones JA, Porcu P, Baiocchi R, Christian BA, Byrd JC, Flynn J, Penza S, Devine SM, Blum KA. "Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma." Clinical Lymphoma Myeloma & Leukemia. Vol. 15, no. 5. (May 2015.): 278-285.

Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA. "Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)." American Journal Of Hematology. Vol. 90, no. 4. (April 2015.): 327-333.

Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, Rassenti LZ, Kipps TJ, de la Chapelle A, Byrd JC. "Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia." Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 112, no. 14. (April 2015.): 4322-4327.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma." British Journal Of Haematology. Vol. 169, no. 5. (June 2015.): 701-710.

Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA. "Jumping translocations, a novel finding in chronic lymphocytic leukaemia." British Journal Of Haematology. Vol. 170, no. 2. (July 2015.): 200-207.

Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ.. "Hypermorphic mutation of phospholipase C, gamma 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation." Blood. Vol. 126, no. 1. (July 2015.): 61-68.

Flynn JM, Jones J, Johnson A, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever M, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. "Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia." Leukemia. Vol. 29, no. 7. (July 2015.): 1524-1529.

 

Reference Works

April 1993 J.M. Flynn, J. Gerhart, B. Callihan, T. Lucas, D. Clawson and M. George-Weinstein."Modulation of Myogenesis of Segmental Plate Mesoderm Cells in Serum-free Medium" .
May 1993 Gerhart J, Foti G, Miehle C, Callihan B, Flynn JM, Lash J, George-Weinstein M."Epiblast Lateral to the Primitive Streak Undergoes Skeletal Myogenesis In Vitro" Bethesda.
January 1994 Gerhart JV, Reed RA, Capparella JN, Flynn JM, George-Weinstein M."Developmental Potential of Chick Embryo Epiblast Cells: Differentiation in the Absence of Gastrulation and Tissue Interactions" Hoboken.
January 1994 Flynn JM, Gerhart JV, Foti G, Miehle C, Callihan B, George-Weinstein M."Maturation of Myogenic and Chondrogenic Precursors within the Presomitic Mesoderm" Hoboken.
October 1994 T.C. VanCott, J.M. Flynn, L.D. Loomis, S.C.D. Veit, A.A. Artenstein, D.S. Burke, D.L. Birx."Analysis of the Specificities of V3 Antibody Populations Within Thai Sera Dually Reactive with Clade B and E V3 Peptides" .
May 1997 J.M. Flynn, C. Iudica, E. Bohen and G.J. Dennis."Thrombotic Thrombocytopenic Purpura in Systemic Lupus Erythematosus" .
November 1997 Flynn JM, bohen E, Chaffin DJ, Dennis GJ, Bolan CJ."Thrombotic Microangiopathy and Concurrent Illness: Diagnostic Dilemma and Drain on Life and Resources" .
May 1998 Flynn JM, Murphy FT, Fukuda M, Gillilan WR, Dennis GJ."Neuro-Behcet’s: An Unusual Presentation of an Uncommon Disease" .
May 1998 Daniels JT, Flynn JM, Drabick J, Byrd JC."Acute Myelogenous Leukemia FAB Subtype M0" .
November 1998 Flynn JM, Dawson Na, Howard RS, Byrd JC."Second Primary Malignancies in B-Cell Chronic Lymphocytic Leukemia: Type and Optimal Time to Monitor Patients" .
January 1999 Rupard EJ, Argyros GJ, Flynn JM."Implications of Determining the Job Fitness of Political Leaders: The Case of Franklin Delano Roosevelt" .
January 1999 Passamonti ML, Flynn JM, Wortmann GW."Management of Internal Jugular Vein Septic Thrombophlebitis and Resultant Pulmonary Embolism with Low Molecular Weight Heparin" .
November 1999 Perkins JG, Flynn JM, Howard RD, Byrd JC."Frequency and Type of Serious Infections in Fludarabine0refracory B-cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Implications for LCinical Trials in this Patient Population" .
November 1999 Flynn JM, Byrd JC, Diehl LF."The Causes of Death and the Impact of Age on the Survival of Patients with Chronic Lymphocytic Leukemia" .
May 2000 Glister B, Willis C, Flynn JM."Hematuria in a Young Male: A rare Case of Bladder Cancer" .
November 2000 Flinn IW, Sickler J, Lucas M, Buj V, Waymer S, Shinn C, Shabooti M, Flynn JM, Diehl L, Byrd JC."Randomized Trial of Early versus Delayed GM-CSF with Campath-1H:Preliminary Feasibility and Correlative Biologic Studies Results" .
November 2001 Flynn JM, Kaplan K, Wang H, Petrovics G, Shrivastava S, Byrd JC, Moul J."The Expression of 1D10 Antigen in Prostate Cancer Tissue" .
November 2002 Pearson MD, Buj V, Shinn C, Waymer SF, Sickler J, Flynn JM, Lucas MS, Flinn IW, Byrd JC."GM-CSF Treatment Does Not Up-regulate Expression of CD20 in vivo in Patients with Chronic Lymphocytic Leukemia" .
January 2002 Brechbiel MW, Milenic DE, Garmestani K, Abdulla A, Overstreet T, Flynn J."Radioimmunotherapy of Intraperitoneal Disseminated Disease: Preliminary Evaluation of Herceptin as a Radioimmunoconjugate" .
January 2005 Mansfield B, Shriver CD, Yip P, Hitt B, Hooke J, Somiari S, Flynn J, Liebman M."A Serum Pattern Predictive of Breast Cancer" .
November 2008 Blum KA, Liu Z, Lucas DM, Baiocchi R, Lin TS, Benson D, Devine SM, Jones J, Andritsos L, Flynn J, Cheng P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC."A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation" . : 3169
November 2008 Benson D, Andritsos L, Hamadani M, Lin TS, Flynn J, Jones J, Blum W, Elder P, Lozanski G, Byrd J, Devine S."Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation" . : 3300
November 2008 Andritsos L, Hamadani M, Heerema NA, Benson D, Hofmeister CC, Blum W, Flynn J, Jones JA, Elder P, Lin TS, Lozanski G, Byrd JC, Devine S."Attainment of Minimal Residual Disease negative State is Crucial for Successful Outcome of Reduced Intensity conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic leukemia (CLL)" . : 2170
May 2008 Lin TS, Andritsos LA, Jones JA, Fischer B, Heerema A, Blum KA, Flynn JM, Moran ME, Phelps MA, Grever MR, Byrd JC."Activity of the Cyclin-dependent Kinase (CDK) inhibitor Flavopiridol in Relapsed, Genetically High Risk Chronic lymphocytic Leukemia (CLL)." . : 7007
May 2008 Flynn JM, Andritsos LA, Lin TS, Byrd JC, Jones JA."Second Primary Malignancies after Chronic Lymphocytic Leukemia" . : 9632
November 2008 Wagner AJ, Hertlein EK, Raymond CA, West DA, Flynn JM, Lin T, Johnson AJ, Byrd JC."17-DMAG Targets the NF-kB Family of Proteins to Induce Apoptosis in CLL: Clinical implications of Hsp90 Inhibition" . : 381
November 2008 May SE, Kashishian A, Lin TS, Jones JA, Flynn JM, Ulrich RG, Chen H, Yu AS, Puri KD, Lannutti BJ, Giese NA, Byrd JC, johnson AJ."CAL-101, a Selective Inhibitor of the p110 Isoform of Phosphatidylinositor 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of this Disease" . : 3165
November 2008 Lin TS, Heerema NA, Lozanski G, Fischer B, Blum KA, Andritsos LA, Jones JA, Flynn JM, Moran ME, Mitchell S, Johnson AJ, Phelps MA, Grever MR, Byrd JC."Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk cytogenetic Abnormalities" . : 46
November 2008 Jones JA, Flynn JM, Byrd JC."Rates of Preventable hospitalization for Ambulatory Care Sensitive Conditions (ACSCs) among Patients with Lymphoid Malignancies (LM)." . : 873
November 2008 Jones JA, Byrd JC, Flynn JM, Hofmeister C."Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (" . : 112
December 2008 Blum KA, Baiocchi RA, Alinari L, Lin TS, Porcu P, Jones J, Flynn, Hicks W, Lucas MS, Wei L, Johnston JS, Byrd JC."A Phase II Trial of induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory mantle Cell (MCL) and Follicular (FL) non-Hodgkin's Lymphoma" Washington. : 3053
January 2009 Andritsos L, Furman R, Flinn IW, Foreno-Torres A, Flynn JM, Stromatt SC, Byrd JC>."A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL." .
January 2009 Byrd JC, Lapalombella R, Ramanunni A, Andritsos LA, Flynn JM, Baum P, Thompson P, Muthusamy N.."Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regularion of the BH3 family member BIM." .
January 2009 Jones JA, Flynn JM, Moran M, Lin T, Byrd J.."Trends in pneumonia (PNA) hospitalization among patients (pts) with chronic lymphocytic leukemia (CLL)" .
December 2009 Flynn JM, Johnson AJ, Wiley E, Hu W, Hessler J, Smith LL, Lucas DM, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC.."The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia" Washington.
December 2010 Blum KA, Ruppert AS, Woyach JA, Jones JJ, Andritsos LA, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC.."Risk Factors for Tumor Lysis Syndrome (TLS) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol." Washington. : 1386
December 2010 Blum KA, Jones JJ, Andritsos L, Flynn JM, Deam D, Heerema NA, Phelps M, Johnson AJ, Grever MR, Byrd JC.."Phase I Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)." Washington. : 2472
December 2010 Baiocchi RA, Flynn JM, Jones JJ, Blum KA, Hofmeister CC, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC.."Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients." Washington. : 3966
December 2010 Woyach JA, Rupper AS, Blum KA, Jones JJ, Flynn JM, Johnson AJ, Grever MR, Byrd JC, Heerema NA."Response, Progression-Free Survival and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities." Washington. : 2456
December 2010 Stephens DM, Ruppert AS, Blum KA, Jones JJ, Flynn J, Johnson AJ, Ji J, Phelps M, Grever MR, Byrd JC.."Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients." .
December 2010 Mahoney E, Johnson AJ, Hessler J, Gupta SV, Herman SEM, Andritsos L, Jones JJ, Flynn J, Lucas DM, Grever MR, Byrd JC.."Autophagy Is a Relevant Cellular Process in CLL and Contributes to Drug Resistance of Flavopiridol." .
December 2010 Jones JJ, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Deam D, Flynn JM, Johnson AJ, Phelps MA, Porcu P, Byrd JC, Grever MR.."Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin’s Lymphoma." Washington. : 2834
December 2010 Johnson AJ, Smith LL, Wagner AJ, Hessler J, Flynn J, Jones JJ, Zhang X, Lehman A, Jarjoura D, Grever MR, Bannerji R, Byrd JC.."Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis in CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines." .
December 2010 Jaglowski SM, Flynn JM, Jones JJ, Lin TS, Fischer B, Scholl D, Elder P, Devine SM, Grever MR, Byrd JC.."Flavopiridol is an Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant." Washinton. : 2383
December 2010 Flynn JM, Jones JJ, Andritsos L, Blum KA, Johnson JA, Hessler J, Wiley E, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC.."Update on the Phase I Study of the cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration." Washington. : 1396
November 2011 Cohen JB, Hall N, Ruppert AS, Jones JJ, Porcu P, Baiocchi RA, Penza S, Benson DM, Adritsos LA, Flynn JM, Devine SM, Blum KA.."The Prognostic Value of FDG PET/CT Prior to autologous Stem Cell Transplant in Mantle Cell Lymphoma" Washington. : 3113
November 2011 Christian B, Alinari L, Jones JJ, Benson DM, Flynn JM, Porcu P, Lustberg ME, Phelps M, Poi M, Chung D, Quinion C, Byrd JC, Wegener W, Goldenberg DM, Baiocchi RA, Blum KA.". Results of a Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin’s Lymphoma" Washington. : 3707
December 2011 Shruti J, Staubli J, Herman EMS, Andritsos LA, Jones JJ, Flynn JM, Mo X, Johnson AJ, Thompson P, Algate PA, Stromatt S.."CLL – Biology and Pathophysiology, Excluding Therapy: Receptor Signaling in CLL" Washington.
December 2011 Shruti J, Staubli J, Herman EMS, Andritsos LA, Jones JJ, Flynn JM, Mo X, Johnson AJ, Thompson P, Algate PA, Stromatt S."Results of a Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin’s Lymphoma Results" Washington.
December 2011 Christian B, Alinari L, Jones JJ, Benson DM, Flynn JM, Porcu P, Lustberg ME, Phelps M, Poi M, Chung D.."Donor B-Cell Alloantibody Deposition and Germinal Center Formation are Required for the Development of Murine Chronic GVHD and Bronchiolitis Obliterans" Washington.
December 2011 Christian B, Alinari L, Jones JJ, Benson DM, Flynn JM, Porcu P, Lustberg ME, Phelps M, Poi M, Chung D.."Clinical Allogeneic and Autologous Transplantation Poster Presentation" Washington.
June 2011 Flynn JM."Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL." Alexandria. : 6623
December 2011 Blum KA, Wei L, Jones JA, Andritsos LA, Flynn J, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson AJ, Grever MR, Byrd JC.."Activity of Combined Flabopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial." Washington. : 3910
December 2011 Blum K, Wei L, Jones JJ, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson AJ, Grever MR."The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma" Washington.
December 2011 Blum K, Wei L, Jones JJ, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson AJ, Grever MR."Experimental Transplantation – Immune Function, GVHD and Graft-versus-Tumor Effects. Novem Regulatory Pathways in GVHD" Washington.
December 2011 Baiocchi R, Penza S, Benson DM Jr, Andritsos LA, Flynn JM, Devine SM, Blum KA."CLL – Therapy, excluding Transplantation. Poster Presentation." Washington.
December 2011 Baiocchi R, Penza S, Benson DM Jr, Andritsos LA, Flynn JM, Devine SM, Blum KA."Targeting the KIT Ativating Switch ontrol Pocket: A Novel Mechanism to Inhibit Mast Cell Activation and KIT D816V Neoplastic Mast Cell Proliferation Result" Washington.
November 2011 Lapalombella R, Ramanunni A, Yeh YY, Wang L, Jha S, Staubli J, Hermann SEM, Andritsos LA, Jones JJ, Flynn JM, Mo X, Johnson AJ, Thompson P, Algate PA, Stromatt S, Freitas MA, Muthusamy N, Byrd JC.."Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals" Washington. : 622
June 2012 Stephens DM, Maddocks K, Andritsos L, Baiocchi R, Jones JJ, Phelps M, Johnson AJ, Smith L, Grever MR, Byrd JC, Flynn JM.."Phase I Feasibility Trial of cyclophosphamice, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients with High-Risk B-cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)." n/a.
July 2012 Jones J, Flynn J, Andritsos L, Johnson A, Blum K, Wiley E, Small K, Grever M, Graef T, Bannerji R, Byrd J.."Phase I Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)" n/a.
December 2012 Hofmeister C, Liu A, Bowers MA, Porcu P, Flynn JM, Christian B, Baiocchi RA, Benson DM, Andritsos LA, Greenfield CN, Sell M, Geyer S, Byrd JC, Grever MR."Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma" Atlanta. : abstract 2955
December 2012 Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith LL, Smucker, KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman A, Furman RR, Sharman J, Mishra A, Caligiuri MA, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC."Ibrutinit is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells" Atlanta. : abstract 775
December 2012 Cohen JB, Rupert AS, Heerema NA, Jones JA, Porcu P, Baiocchi RA, Christian B, Byrd JC, Flynn JM, Penza S, Andritsos LA, Devine SM, Blum KA."Complex Karyotype (CK) is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL)" Atlanta. : abstract 2691
December 2012 Cohen JB, Geyer S, Lozanski G, Zhou W, Heerema NA, Jones JA, Porcu P, Christian B, Baiocchi RA, Maddocks K, Flynn JM, Devine SM, Blum KA."Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin’s Lymphoma (NHL) is Associated with Prolonged Progression-Free Survival (PFS)" Atlanta. : abstract 2693
June 2012 Stephens DM, Ruppert AS, Christian B, Jones JA, Flynn JM, Porcu P, Baiocchi R, Byrd JC, Dotson EK, Crawford BS, Blum KA."Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL)" n/a.
June 2012 Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer SM, Woyach JA, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James DF, Lowe AM, Hedrick E, Byrd JC."A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases" n/a. : abstract 6508
September 2012 Cocci PF, Altman J, Bhati S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger DC, Orr KM, Pappo AS, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack BJ, Sundar H, Shead DA."Adolescent and Young Adult Oncology" Atlanta. : 1112
December 2012 Morrison E, Flynn JM, Jones JA, Byrd JC, Andersen BL."Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia" n/a. : abstract 2075
December 2012 Chappell DL, Dubovsky JA, Andritsos LA, Flynn JM, Jones JA, Byrd JC, Muthusamy N."Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling" n/a. : abstract 3866
December 2012 Blum KA, Christian B, Flynn JM, Jaglowski SM, Jones JA, Maddocks K, Byrd."A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)" n/a. : abstract 2955
December 2012 Mahoney E, Cole SL, Maddocks K, Flynn JM, DO, Jones JA, Zhang X, Byrd JC, Johnson AJ."Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies" n/a. : abstract 2473
December 2012 Maddocks K, Hertlein EK, Flynn JM, Andritsos LA, Wagner AJ*,Chen TL, Phelps MA, Grever MR, Johnson AJ, Byrd JC, Jones J."Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)" n/a. : abstract 1800
November 2013 Stephens D, Stark A, Wierda W, Jones J, Maddocks K, Jaglowski S, Andritsos L, Flynn J, Grever M, Lozanski G, Tam C, O'Brien S, Keating M, Muthusamy N, Abruzzo L, Heerema N, Byrd JC."Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients" n/a. : abstract 4128
November 2013 Stephens D, Stark A, Jones J, Woyach J, Maddocks K, Jaglowski S, Andritsos L, Flynn J, Grever M, Lozanski G, Johnson A, Muthusamy N, Heerema N, Byrd JC."Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype" n/a. : abstract 2872
November 2013 McWilliams E, Cheney C, Jones J, Flynn J, Maddocks K, Andritsos L, Huet H, Gram H, Baeck J, Muthusamy N, Byrd JC."B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo" n/a. : abstract 4185
November 2013 Flynn J, Andritsos L, Jones J, Johnson A, Maddocks K, Wiley E, Small K, Kyung Im E, Grever M, Bannerji R, Byrd JC, Zhou H."Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)" n/a. : abstract 871
May 2013 Woyach JA, Flynn JM, Jones JA, Andritsos LA, Lucas M, Chase W, Yang Y, Lucas DM, Sass E, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC."Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL)" n/a. : abstract 7077
December 2014 Jones JA, Geyer S, Andritsos LA, Awan F, Flynn JM, Maddocks KJ, Bingman A, Johnson AJ, Heerema NA, Brookfield C, Byrd JC, Grever MR."Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study" n/a. : abstract 329
May 2014 Woyach JA, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L, Gordon A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, MR Grever, Johnson AJ, Byrd JC, Maddocks KJ."Association of Disease Progression on Ibrutinib Therapy With The Acquisition of Resistance Mutations: A Single-Center Experience of 267 Patients" n/a. : abstract 7010
December 2014 Stephens DM, Beckwith KA, Cheney C, Mo X, Flynn JM, Jones JA, Maddocks KJ, Heider KH, Muthusamy N, Byrd JC."4681 BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia" n/a. : abstract 4681
December 2014 Martin P, Maddocks KJ, Noto K, Christian B, Furman RR, Andritsos LA, Flynn JM, Jones JA, Ruan J, Chen-Kiang S, Di Liberto M, Leonard JP, Blum KA."Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma" n/a. : abstract 3047
May 2014 Lester J, Stout R, Crosthwaite K, Jones R, Shapiro CL, Flynn JM, Andersen BL."Distress in Acute Leukemia and Breast Cancer Survivors During Early Survivorship: Evidence to Guide Survivorship Care Planning" n/a. : abstract e20564
December 2014 Maddocks KJ, Cohen JB, Christian B, Flynn JB, Jaglowski SM, Blum KA."A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)" n/a. : abstract 329
December 2014 Rogers KA, Woyach JA, Andritsos LA, Awan F, Blum KA, Flynn JM, Jaglowski S, Lozanski G, Maddocks KJ, Byrd JC, Jones JA."Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib" n/a. : abstract 1997

Presentations

"Modulation of Myogenesis of Segmental Plate Mesoderm Cells in Serum-free Medium." Presented at Mol. Biol. Cell, . (April 1993)

"Maturation of Myogenic and Chondrogenic Precursors within the Presomitic Mesoderm." Presented at AWIS-PHL Conference, . (April 1994)

"Analysis of the Specificities of V3 Antibody Populations Within Thai Sera Dually Reactive with Clade B and E V3 Peptides.." Presented at Conference on Advances in Aids Vaccine Development, . (November 1994)

"Thrombotic Thrombocytopenic Purpura/Plasma Exchange Workshop." Presented at Army Scientific Meeting of the American College of Physicians, . (November 1997)

"Thrombotic Microangiopathy and Concurrent Illness: Diagnostic Dilemma and Drain on Life and Resources." Presented at Army Scientific Meeting of the American College of Physicians, General Session, . (November 1997)

"Neuro-Behcet's: An Unusual Presentation of an Uncommon Disease." Presented at American College of Physicians, Rheumatology Session, . (November 1997)

"Thrombotic Thrombocytopenic Purpura in Systemic Lupus Erythematosus." Presented at American College of Physicians Associates Meeting, . (May 1997)

"Neuro-Behcet's: An Unusual Presentation of an Uncommon Disease." Presented at American College of Physicians Associates meeting, . (May 1998)

"Second Primary Malignancies in B-Cell Chronic Lymphocytic Leukemia (CLL): Type and Optimal Time to Monitor Patients." Presented at American College of Physicians, . (November 1998)

"Second Primary Malignancies in B-Cell Chronic Lymphocytic Leukemia (CLL): Type and Optimal Time to Monitor Patients.." Presented at IWCLL VII International Workshop on CLL, . (October 1999)

"Lung Cancer Medicine." Presented at Oncology Pharmacy Continuing Education Course, Washington, DC. (October 1999)

"Second Primary Malignancies in B-Cell Chronic Lymphocytic Leukemia (CLL): Type and Optimal Time to Monitor Patients.." Presented at American College of Physicians, Regional Meeting, . (January 1999)

"Second Primary Malignancies in B-Cell Chronic Lymphocytic Leukemia (CLL): Type and Optimal Time to Monitor Patients." Presented at Regional Meeting, . (January 1999)

"Anemia Lecture Series." Presented at Uniformed Services University of the Health Sciences, Bethesda, MD. (April 2000)

"Acute Lymphocytic Leukemia and Disseminated Candidiasis." Presented at Management Conference, Washington, DC. (April 2000)

"Coagulation Pathways Services." Bethesda, MD. (October 2000)

"The Ethics of Pain Management, Walter Reed Army Medical Center Ethics Series." Presented at Walter Reed Army Medical Center, Washington, DC. (October 2000)

"Review of Lung Cancer for Oncology Nurses." Presented at Nursing lecture Series, Washington, DC. (July 2001)

"Everything You Wanted to Know About Colon Cancer." Presented at Walter Reed Army Medical Center, Washington, DC. (July 2001)

"The Ethics of Pain Management." Presented at Walter Reed Army Medical Center, Washington, DC. (April 2001)

"Rituximab Therapy in Chronic Lymphocytic Leukemia." Presented at National heart, Lung and Blood Institute, Bethesda, MD. (June 2001)

"The Expression of 1D10 Antigen in Prostate Cancer Tissue." Presented at Hematology-Oncology Session, Army Chapter, . (November 2001)

"The Expression of 1D10 Antigen in Prostate Cancer Tissue." Presented at American College of Physicians, . (November 2001)

"Lung Cancer: Management Conference." Presented at Walter Reed Army Medical Center, Washington, DC. (October 2001)

"The Ethics of Pain Management, Walter Reed Army Medical Center Ethics Series." Presented at Walter Reed Army Medical Center, Washington, DC. (October 2001)

"An Overview of Cancer Medicine." Presented at Laboratory Medicine Course, Washington, DC. (December 2001)

"Lung Cancer. National Capital Area Chemotherapy Course.." Presented at Walter Reed Army Medical Center, Washington, DC. (January 2002)

"Colon Cancer. National Capital Area Chemotherapy Course.." Presented at Walter Reed Army Medical Center, Washington, DC. (January 2002)

"Issues in the Management of Thromboembolic Disease." Presented at Grand Rounds, Landstuhl, DE|DEU. (December 2002)

"The Ethics of Pain Management, Walter Reed Army Medical Center Ethics Series." Presented at Walter Reed Army Medical Center, Washington, DC. (December 2002)

"The Expression of 1D10 Antigen in Prostate Cancer Tissue." Presented at American College of Physicians, Army Chapter, . (May 2002)

"Second Primary Malignancies in Chronic Lymphocytic Leukemia and the Association with Human Papilloma Virus." Presented at Bailey K. Ashford Award Program, . (May 2002)

"Second Primary Malignancies in Chronic Lymphocytic Leukemia and the Association with Human Papilloma Virus." Presented at Bailey K. Ashford Award Program, . (May 2002)

"Analysis of Banked Sera for Molecular and Biochemical Changes Associated with Development of Breast Cancer." . (June 2002)

"Breast Cancer Screening." Presented at Grand Rounds, Landstuhl, DE|DEU. (October 2003)

"Oncologic Emergencies. Nursing Educational Course." Presented at Landstuhl Regional Medical Center, Landstuhl, DE|DEU. (January 2003)

"Chemotherapeutics. Nursing Education Course." Presented at Landstuhl Regional Medical Center, Landstuhl, DE|DEU. (January 2003)

"Funding Initiatives in the United States Military." Presented at Grand Rounds, Landstuhl, DE|DEU. (December 2003)

"Breast Cancer Awareness Lecture Series." . (October 2003)

"Testicular Cancer." Landstuhl, DE|DEU. (January 2004)

"Breast Cancer Center Development: The Military Model." Presented at National Conference of Breast Cancer Centers, . (February 2004)

"Breast Cancer Center Development: The Military Model." Presented at National Conference of Breast Cancer Centers, . (February 2004)

"Primary Systemic Therapy and Adjuvant Therapy in Breast Cancer." Presented at Medical-Surgical Conference, . (May 2004)

"Coagulation Evaluation for the Internist." Presented at Medical-Surgical Conference, . (May 2004)

"Breast Cancer 2004: Primary Systemic Therapy and Adjuvant Therapy in Breast Cancer." Presented at Medical-Surgical Conference, . (May 2004)

"Clinical Correlation of the Complete Blood Count." Presented at Laboratory Meeting, Landstuhl, DE|DEU. (January 2004)

"Chemotherapeutics. Nursing Education Course." Presented at Landstuhl Regional Medical Center, Landstuhl, DE|DEU. (January 2004)

"Oncologic Emergencies. Nursing Education Course." Presented at Landstuhl Regional Medical Center, Landstuhl, DE|DEU. (January 2004)

"Breast Cancer Awareness Lecture Series." . (September 2004)

"The Complete Blood Count. Common Diagnoses and What You Can learn from a Simple Blood Test.." Landstuhl, DE|DEU. (October 2005)

"Anemias and Other Common Hematological Diagnoses.." Presented at Grand Rounds, . (October 2005)

"Cancer Management in 2005." Prishtina. (November 2005)

"Cancer Management in 2005." Prishtina. (November 2005)

"Breast Cancer Care in 2006." Presented at European Regional Med-Surg Conference, Willingen, DE|DEU. (April 2006)

"Business Modeling and Electronic Medical Records." Presented at Commanders Conference, Heidelberg, DE|DEU. (November 2006)

"Hematopoietic Cell transplantation for Acute Myeloid Leukemia." Presented at Comprehensive Cancer Center Grand Rounds, Columbus, OH, US|USA. (December 2006)

"Hematology Census Weekly Meeting." Presented at The Ohio State University, Division of Hematology and Oncology, Columbus, OH, US|USA. (July 2007)

"Review and Interpretation for the 2007 ASCO, AACR and other Major International Meetings." Columbus, OH, US|USA. (June 2007)

"Second Primary Malignancies in B-Cell Chronic Lymphocytic Leukemia (CLL): Type and Optimal Time to Monitor Patients.." Presented at Hematology-Oncology Session, Army Chapter, . (January 2008)

"American Society of Hematology Review." Columbus, OH. (January 2008)

"Wyandot Memorial Hospital." Presented at Grand Rounds, Upper Sandusky, OH. (July 2008)

"Licking Memorial Hospital." Presented at Grand Rounds, Newark, OH. (July 2008)

"Oncologic Emergencies." Presented at Medical Student Lecture Series, Columbus, OH. (April 2008)

"Kettering Medical Center." Presented at Grand Rounds, Kettering, OH. (April 2008)

"Ohio Chapter Poster Judging." Columbus, OH. (January 2009)

"ASH Review." Presented at Comprehensive Cancer Center ASH Review, Columbus, OH, US|USA. (January 2009)

"Exciting New Developments in Hematology." Presented at Comprehensive Cancer Center Grand Rounds, . (May 2009)

"Lymphoma Update for the Internist." Presented at Fall Medicine Update, State College, PA. (November 2009)

"The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.." Presented at 51st Annual American Society of Hematology Conference, New Orleans, LA. (December 2009)

"Patient Access to New Drugs and What's Happening or Not.." Presented at Trends in Treating CLL Conference, ON, CA|CAN. (April 2009)

"How to Best Use New Therapies in CLL.." Presented at Trends in Treating CLL Conference, ON, CA|CAN. (April 2009)

"Medical Training in 2012." Presented at Alpha Epsilon Delta Pre-Medical Honor Society, Columbus, Ohio. (January 2010)

"Cancer in Adolescents and Young Adults." Presented at OSU CCC 12th Annual Scientific Meeting, Columbus, Ohio. (February 2010)

"A Chorus Line of Leadership Directs Big Bang Performance." Presented at EPIC 2010 Users' Group Meeting, Madison, WI, US|USA. (September 2010)

"Review of Diagnosis and Treatment of Non-Hodgkin's Lymphoma." Presented at Upper Valley Medical Center Tumor Board Lecture, Troy, Ohio. (May 2011)

"ASH Review." Presented at 2010 American Society of Hematology Review, Columbus, Ohio. (January 2011)

"Cancer Therapy Evaluation Program (CTEP) Early Drug Development Meeting." Presented at NCI Spring 2011 National Cancer Institute, Washington, District of Columbia. (March 2011)

"NCCN Adolescent and Young Adult Oncology Panel Meeting." Presented at National Comprehensive Cancer Network, Philadelphia, Pennsylvania. (April 2011)

"Lymphoma in 2011." Presented at 2nd Annual Long Term Health aftyer Blood Cancer Conference, Columbus, Ohio. (April 2011)

"Clinical Outcome and Treatment Choices for CLL Patients over the Age of 65." Presented at CLL LIVE 2012 Conference, Niagara Falls, ON, CA|CAN. (April 2012)

"3rd Annual Long-Term Care after Blood Cancer Conference." Presented at James Care for Life and The Leukemia and Lymphoma Society, Columbus, Ohio. (April 2012)

"Chronic Leukemias." Presented at MedNet Webcast, Columbus, Ohio. (January 2012)

"Pennies for Patients Researcher Visit." Presented at Leukemia and Lymphoma Society, Columbus, Ohio. (February 2012)

"Chronic Lymphocytic Leukemia." Presented at 2013 Highlights of Ash in North America, Dallas, TX, US|USA. (January 2013)

"Chronic Lymphocytic Leukemia." Presented at 2013 Highlights of Ash in North America, San Francisco, CA, US|USA. (February 2013)

"Cancer Survivorship Implementation and Evaluation." Presented at Essentials of Cancer Survivorship Workshop, Midwest Consortium for Cancer Survivorship Education and Research, Cincinnati, OH, US|USA. (November 2014)

"What’s New in Chronic Lymphocytic Leukemia (CLL)?." Presented at Aultman Cancer Center’s 14th Annual Cancer Conference, North Canton, OH, US|USA. (September 2014)

"The Incidentaloma’s: How and When to Rule out Cancer, The Appropriate Follow-up and Management." Presented at Update in Internal Medicine, State College, PA, US|USA. (October 2014)

"Cancer 101." Presented at National Association of Cancer Center Development Officers (NACCDO) Annual Conerence, Columbus, OH, US|USA. (March 2014)

"Change Management in the Age of Affordable Care." Presented at National Comprehensive Cancer Network’s (NCCN) Best Practices meeting, Columbus, OH, US|USA. (September 2014)

"Organizational Structure and Program Evaluation." Presented at Essentials of Cancer Survivorship Workshop, Midwest Consortium for Cancer Survivorship Education and Research, Cincinnati, OH, US|USA. (November 2014)

"New Developments in the Treatment of Lymphomas/Leukemias." Presented at 18th Annual Lewis A. Schmidt, MD Memorial Cancer Symposium, Gallipolis, OH, US|USA. (November 2014)

"Physician Satisfaction and Dissatisfaction: Putting the Joy Back into Clinical Practice." Presented at National Comprehensive Cancer Network’s (NCCN) Best Practices meeting, Hollywood, FL, US|USA. (March 2015)

"Discussion." Presented at National Oncologic Emergencies Research Consortium, Rockville, MD, US|USA. (March 2015)

"An Opportunity to Ask the Experts." Presented at CLL Live 2015 Conference, Niagra Falls, ON, CA|CAN. (April 2015)

"Psycho-Social Aspects of CLL, Unreated." Presented at CLL Live 2015 Conference, Niagra Falls, ON, CA|CAN. (April 2015)

"When to Call the Doctor." Presented at CLL Live 2015 Conference, Niagra Falls, ON, CA|CAN. (April 2015)

 

Professional Activities

present Smoking Cessation Lecture Series.
present Veteran's Day Panel Moderator. The Ohio State University.
present Ulman Cancer Fund Event Speaker. Ulman Cancer Fund for Young Adults. Columbus, OH.
present Black History Month Celebration Presenter. The Ohio State University. Columbus, OH.
present Mirrors Sophomore Honorary Benefit Speaker. Columbus, OH.
present Presentation to school students. Kilborne Middle School. Worthington, OH.
present Man and Woman of the Year Gala Speaker. Leukemia and Lymphoma Society. Columbus, OH.
present Expansion to Ohio East Hospital. Eastside Fellowship Ministry. Columbus, OH.
2001 - present Radiation Safety Course. Uniformed Services University. Bethesda, MD.
2002 - present Radiation Safety Course. National Institutes of Health. Bethesda, MD.
2003 - present Breast Cancer Awareness Lecture Series, Keynote Speaker.
2004 - present Wellness Lecture Series. European Educator Group.
2004 - present Breast Cancer Awareness Lecture Series, Keynote Speaker.
2004 - present Breast Cancer Awareness Lecture Series, Keynote Speaker.
2004 - present Testicular Cancer Awareness lecture. Kaiserslautern High School.
2006 - present Breast Cancer Awareness lecture Series, Keynote Speaker.
2006 - present Breast Cancer 2006:PWOC.
2006 - present Breast Cancer Awareness.
2008 - present Columbus Health Radio Program. Columbus, OH.
2008 - present Learning Session. Sponsored by the Leukemia and Lymphoma Society. Columbus, OH.
2008 - present Learning Session. Leukemia and Lymphoma Society. Columbus, OH.
2008 - present Presentation to High School Students. Franklin Heights High School. Columbus, OH.
2008 - present Presentation. Zanesville Leukemia & Lymphoma Society. Zanesville, OH.
2008 - present Presentation. Scioto County Medical Society. Portsmouth, OH.
2008 - present Patient Support Program. Leukemia and Lymphoma Society Patient Support Program. Columbus, OH.
2009 - present Presentation to High School Students. Marysville High School. Marysville, OH.
2009 - present Presentation to high school students. Pleasantview Middle School. Grove Cith, OH.
2009 - present Presentation to high school students. Southeastern Local Schools. South Charleston, OH.
2010 - present Presentation to students. Circleville High School. Circleville, OH.
2010 - present Presentation to students. St. Patrick Middle School. London, OH.
2010 - present Presentation to high school students. Whetstone High School, AP Chemistry Class. Columbus, OH.
2010 - present Tom Joyner Morning Show. 9th Annual Take a Loved One to the Doctor Day Campaign.
2010 - present Presentation to high school students. Grant Middle School. Columbus, OH.
2003 Assistant Coach: 7-8 year old Basketball Youth Program.
2003 Assistant Coach: 5-6 yr. old Soccer Youth Program.
2004 Assistant Coach: 5-6 year old Baseball Youth Program.
2001 - 2005 Air Force Office of Scientific Research.
2003 - 2005 Coach: 5-6 year old Basketball Youth Program.
2005 - 2006 Coach: 7-8 year old Basketball Youth Program.
2006 Volunteer Instructor of Karate.
2006 - 2007 11-12 year olf Basketball Youth Program.
2007 - 2008 Volunteer religious educator. St Joan of Arc Parish, Powell, OH. Powell, OH.